CL2018003504A1 - Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos. - Google Patents
Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.Info
- Publication number
- CL2018003504A1 CL2018003504A1 CL2018003504A CL2018003504A CL2018003504A1 CL 2018003504 A1 CL2018003504 A1 CL 2018003504A1 CL 2018003504 A CL2018003504 A CL 2018003504A CL 2018003504 A CL2018003504 A CL 2018003504A CL 2018003504 A1 CL2018003504 A1 CL 2018003504A1
- Authority
- CL
- Chile
- Prior art keywords
- antineoplastic agents
- derivatives useful
- substituted
- carbonucleoside derivatives
- substituted carbonucleoside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Silicon Polymers (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
LOS COMPUESTOS DE LA FÓRMULA GENERAL (1), PROCESOS PARA LA PREPARACIÓN DE ESTOS COMPUESTOS, COMPOSICIONES QUE CONTIENEN ESTOS COMPUESTOS Y LOS USOS DE ESTOS COMPUESTOS.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346226P | 2016-06-06 | 2016-06-06 | |
US201662376856P | 2016-08-18 | 2016-08-18 | |
US201662431714P | 2016-12-08 | 2016-12-08 | |
US201762506076P | 2017-05-15 | 2017-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018003504A1 true CL2018003504A1 (es) | 2019-02-01 |
Family
ID=59071035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018003504A CL2018003504A1 (es) | 2016-06-06 | 2018-12-06 | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos. |
Country Status (42)
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019084470A1 (en) * | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
WO2020243178A1 (en) * | 2019-05-30 | 2020-12-03 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
EP3720495A4 (en) * | 2017-12-05 | 2021-06-02 | Angex Pharmaceutical, Inc. | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS |
CN108997309A (zh) * | 2018-07-17 | 2018-12-14 | 中国科学技术大学苏州研究院 | 一种吡唑-4-芳基衍生物的制备方法 |
EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
EP3914597A1 (en) | 2019-01-23 | 2021-12-01 | Pfizer Inc. | Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative |
CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
RS64972B1 (sr) | 2019-06-10 | 2024-01-31 | Lupin Ltd | Inhibitori prmt5 |
TW202128176A (zh) * | 2019-12-18 | 2021-08-01 | 美商輝瑞股份有限公司 | 使用蛋白精胺酸甲基轉移酶5(prmt5)抑制劑之每日一次癌症治療方案 |
IL294400A (en) * | 2020-01-07 | 2022-08-01 | Pfizer | A prmt5 inhibitor for use in the treatment of psoriasis and other autoimmune conditions |
CN111138355A (zh) * | 2020-01-17 | 2020-05-12 | 成都睿智化学研究有限公司 | 一种甲醛取代的氮杂稠环类化合物的制备方法 |
CN115038690A (zh) | 2020-01-31 | 2022-09-09 | 索尔维公司 | 用于制造卤代烷基取代的吡啶化合物的方法 |
WO2021202480A1 (en) * | 2020-04-01 | 2021-10-07 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
WO2022013691A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol |
WO2022013692A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride |
WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
CN100400513C (zh) | 2001-02-22 | 2008-07-09 | 细胞技术研究及开发有限公司 | 用作整合蛋白抑制剂的含环丁烯基团的苯基丙氨酸烯酰胺衍生物 |
US20040043959A1 (en) * | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
EP1987717A1 (de) | 2007-04-30 | 2008-11-05 | Bayer CropScience AG | Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
CN103339132B (zh) * | 2010-12-02 | 2017-02-15 | 株式会社麦迪帕克特 | 嘌呤基吡啶基氨基‑2,4‑二氟苯基磺酰胺衍生物、其药学上可接受的盐、其制备方法及包含其作为活性成分的对Raf激酶具有抑制活性的药物组合物 |
JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
US20160168185A1 (en) | 2013-07-22 | 2016-06-16 | Baylor College Of Medicine | Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment |
EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2016135735A1 (en) * | 2015-02-25 | 2016-09-01 | Outsense Diagnostics Ltd. | Bodily emission analysis |
TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
-
2017
- 2017-06-01 CA CA2969295A patent/CA2969295A1/en active Pending
- 2017-06-02 US US15/612,030 patent/US10220037B2/en active Active
- 2017-06-03 RS RS20211156A patent/RS62351B1/sr unknown
- 2017-06-03 HU HUE17730948A patent/HUE056634T2/hu unknown
- 2017-06-03 KR KR1020217003681A patent/KR20210018529A/ko not_active Application Discontinuation
- 2017-06-03 HR HRP20211449TT patent/HRP20211449T1/hr unknown
- 2017-06-03 JP JP2018563551A patent/JP6553825B2/ja active Active
- 2017-06-03 PL PL17730948T patent/PL3464249T3/pl unknown
- 2017-06-03 DK DK17730948.1T patent/DK3464249T3/da active
- 2017-06-03 WO PCT/IB2017/053295 patent/WO2017212385A1/en unknown
- 2017-06-03 CR CR20180578A patent/CR20180578A/es unknown
- 2017-06-03 GE GEAP201714948A patent/GEP20217211B/en unknown
- 2017-06-03 MA MA45153A patent/MA45153B1/fr unknown
- 2017-06-03 CN CN201780049070.8A patent/CN109890797B/zh active Active
- 2017-06-03 SG SG11201810485SA patent/SG11201810485SA/en unknown
- 2017-06-03 CU CU2018000144A patent/CU24517B1/es unknown
- 2017-06-03 SI SI201730926T patent/SI3464249T1/sl unknown
- 2017-06-03 MX MX2018015094A patent/MX2018015094A/es unknown
- 2017-06-03 BR BR112018075166-9A patent/BR112018075166A2/pt not_active Application Discontinuation
- 2017-06-03 PE PE2018003140A patent/PE20190439A1/es unknown
- 2017-06-03 KR KR1020197000054A patent/KR102215313B1/ko active IP Right Grant
- 2017-06-03 PT PT177309481T patent/PT3464249T/pt unknown
- 2017-06-03 RU RU2018142734A patent/RU2712944C1/ru active
- 2017-06-03 UA UAA201812060A patent/UA124386C2/uk unknown
- 2017-06-03 MY MYPI2018002348A patent/MY196413A/en unknown
- 2017-06-03 LT LTEPPCT/IB2017/053295T patent/LT3464249T/lt unknown
- 2017-06-03 SG SG10202100861TA patent/SG10202100861TA/en unknown
- 2017-06-03 ES ES17730948T patent/ES2890435T3/es active Active
- 2017-06-03 TN TNP/2018/000424A patent/TN2018000424A1/en unknown
- 2017-06-03 AU AU2017279014A patent/AU2017279014B2/en active Active
- 2017-06-03 EP EP17730948.1A patent/EP3464249B1/en active Active
- 2017-06-03 MD MDE20190422T patent/MD3464249T2/ro unknown
- 2017-06-05 TW TW106118476A patent/TWI637945B/zh active
- 2017-06-05 TW TW107130452A patent/TWI667240B/zh active
- 2017-06-05 UY UY0001037274A patent/UY37274A/es unknown
-
2018
- 2018-11-16 ZA ZA2018/07723A patent/ZA201807723B/en unknown
- 2018-11-29 PH PH12018502535A patent/PH12018502535B1/en unknown
- 2018-12-04 CO CONC2018/0013105A patent/CO2018013105A2/es unknown
- 2018-12-04 NI NI201800128A patent/NI201800128A/es unknown
- 2018-12-05 IL IL263505A patent/IL263505B/en active IP Right Grant
- 2018-12-06 SV SV2018005794A patent/SV2018005794A/es unknown
- 2018-12-06 DO DO2018000268A patent/DOP2018000268A/es unknown
- 2018-12-06 EC ECSENADI201890743A patent/ECSP18090743A/es unknown
- 2018-12-06 CL CL2018003504A patent/CL2018003504A1/es unknown
- 2018-12-18 US US16/224,016 patent/US10709709B2/en active Active
-
2019
- 2019-07-04 JP JP2019125220A patent/JP2019194231A/ja active Pending
- 2019-11-15 AU AU2019264640A patent/AU2019264640A1/en not_active Abandoned
-
2021
- 2021-04-08 IL IL282167A patent/IL282167A/en unknown
- 2021-09-16 CY CY20211100815T patent/CY1124798T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003504A1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos. | |
GT201700189A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
UY38070A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
DOP2018000270A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
CU20180027A7 (es) | DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
CL2018001837A1 (es) | Compuestos antiproliferativos y sus composiciones farmacéuticas y usos | |
CO2018004581A2 (es) | Compuestos de criptoficina y productos conjugados, y sus métodos de preparación | |
UY38031A (es) | Hidroxiisoxazolinas y derivados de estos | |
CL2016002089A1 (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CR20180181A (es) | Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
ECSP17063489A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
EA201892498A1 (ru) | Замещенные карбонуклеозидные производные, приемлемые в качестве противораковых агентов |